GlobalData on MSN
J&J’s Caplyta doubles remission rate in MDD patients
J&J presented the new analysis from three Phase III trials of Caplyta in MDD.
The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...
A new medical large language model (LLM) achieved over 91% accuracy in identifying female participants diagnosed with major ...
The American College of Lifestyle Medicine, or ACLM, released a new expert consensus statement on the role of lifestyle ...
The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.
MedPage Today on MSN
Fish oil flopped for kids with major depressive disorder
Adjunctive omega-3 therapy failed to improve moderate-to-severe depression more than place ...
For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.
New TMS biomarkers combined with machine learning accurately classified major depressive disorder. Learn more about this ...
Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical ...
Click Therapeutics’ CEO discusses the first FDA-cleared depression app, migraine treatment breakthrough, and digital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results